CD19 and systemic lupus erythematosus: Elegant pre-clinical studies have suggested that conventional anti-CD19 CAR-T cells can be used to selectively deplete B lymphocytes, which play a role in the pathogenesis of SLE, improving the disease in genetic lupus-prone mice22,25.